Cargando…
Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective
BACKGROUND: Nonsevere hypoglycemia episodes (NSHEs) are associated with clinically adverse outcomes, lower health-related quality of life, increased burden of disease, and reduced work productivity. OBJECTIVE: To estimate prevalence of NSHEs and associated economic outcomes attributable to sulfonylu...
Autor principal: | Farahani, Pendar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6079519/ https://www.ncbi.nlm.nih.gov/pubmed/30123259 http://dx.doi.org/10.1155/2018/3718958 |
Ejemplares similares
-
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Jeon, Ja Young, et al.
Publicado: (2021) -
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012) -
Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes
por: Xie, Yan, et al.
Publicado: (2021) -
Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022) -
Role of Octreotide in Sulfonylurea-Induced Hypoglycemia
por: Zafar, Sheema, et al.
Publicado: (2021)